| Ketoprofen |
![]() Last updated: 06/09/2025 |
![]() |
(Also known as: m-benzoylhydratropic acid ) |
|
|
|
A veterinary non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation | |
|---|---|---|
|
Most commonly prescribed for musculoskeletal pain from soft-tissue injury, osteoarthritis or other bone and joint problems. Also used to reduce or control fevers due to viral or bacterial infections. | |
|
Dogs; Cats; Horses; Goats; Sheep; Pigs |
| Approval status |
|
Approved - usually available as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
|---|---|---|
|
Approved |
| Chemical structure |
|
Ketoprofen exhibits enantiomeric isomerism, meaning it exists as the (R)-ketoprofen and (S)-ketoprofen enantiomers. These arise due to the presence of a chiral centre in its 2-arylpropionic acid structure. Although ketoprofen is typically administered as a racemic mixture (equal parts R and S), only the S-enantiomer is primarily responsible for its anti-inflammatory effects, as it inhibits cyclooxygenase (COX) enzymes and prostaglandin synthesis. The R-enantiomer, while less active in COX inhibition, contributes to analgesic effects and does not amplify inflammatory cytokine production, which may reduce gastrointestinal side effects. Moreover, in mammals, chiral inversion can occur where the R-form partially converts to the S-form, especially in the gastrointestinal tract, influencing the drug’s overall pharmacokinetics and therapeutic profile. | |
|---|---|---|
|
C₁₆H₁₄O₃ | |
|
CC(C1=CC=CC(=C1)C(=O)C2=CC=CC=C2)C(=O)O | |
|
C[C@H](C1=CC=CC(=C1)C(=O)C2=CC=CC=C2)C(=O)O | |
|
DKYWVDODHFEZIM-LLVKDONJSA-N | |
|
InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m1/s1 | |
|
Yes |
|
|
| Common Name | Relationship | Link |
|---|---|---|
| ketoprofen | - | ![]() |
| General status |
|
Anti-inflammatory, Analgesic, Medicinal drug | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Propionic acid based substance | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Synthetic | ||||||||||||||
|
Works by inhibiting the body's production of prostaglandins, thromboxane and other inflammatory mediators | ||||||||||||||
|
[Prostaglandin G/H synthase 1, Inhibitor], [Prostaglandin G/H synthase 2, inhibitor], [High affinity interleukin-8 receptor A] | ||||||||||||||
|
56105-81-8 | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Musculo-skeletal system: Anti-inflammatory & antirheumatic products | ||||||||||||||
|
QM01AE03 | ||||||||||||||
|
No | ||||||||||||||
|
Allowed substance (Table 1: Bovine, Porcine, Equidae) | ||||||||||||||
|
254.28 | ||||||||||||||
|
- | ||||||||||||||
|
(RS)2-(3-benzoylphenyl)-propionic acid | ||||||||||||||
|
(2R)-2-(3-phenylcarbonylphenyl)propanoic acid | ||||||||||||||
|
|
||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
White crystalline solid | ||||||||||||||
| Commercial |
|
|
|||
|---|---|---|---|---|
|
Current | |||
|
Circa 1990, introduced | |||
|
|
|||
|
|
|||
|
Available in a variety of formulations including tablets for oral administration and solutions for injection | |||
|
Ketoprofen is synthesised through a multi-step chemical process that typically begins with 3-methylbenzophenone as the key starting material. In one industrial route, this compound undergoes bromination to form 3-bromo-methylbenzophenone, which is then subjected to a Friedel–Crafts acylation and benzylic oxidation to yield the final ketoprofen structure. A more environmentally friendly method starts from cyclohexanone, which is transformed via Stork enamine alkylation, followed by aldol addition, enol-lactonization, and pyrolytic aromatization, ultimately producing the arylpropionic acid backbone of ketoprofen. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
|
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
500 | E3 E = Manufacturers safety data sheets 3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
93 | E3 E = Manufacturers safety data sheets 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
Max at 255nm | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
| Degradation |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- | ||||||||||
| Soil adsorption and mobility |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
| Fate indices |
|
|
|
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - | |||||||||||||||||||||||||||
| Known soil and groundwater metabolites |
None
| Other known metabolites |
|
|
|
|
||||
|---|---|---|---|---|---|---|---|
| glucuronic acid | - | - | - |
|
|
| Terrestrial ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
62.4 | F4 F = U.S. EPA ECOTOX database / U.S. EPA pesticide fate database / Miscellaneous WHO documents / FAO data, IPCS INCHEM data (US EPA Databases Related to Pesticide Risk Assessment ) Rat4 = Verified data |
High | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
| - | |||||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- |
|
- | - | - | ||||||
|
- | ||||||||||
| Aquatic ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - | ||||||||
|
|
| General |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
High (class II) | - | - | ||||||||
|
62.4 | F4 F = U.S. EPA ECOTOX database / U.S. EPA pesticide fate database / Miscellaneous WHO documents / FAO data, IPCS INCHEM data (US EPA Databases Related to Pesticide Risk Assessment ) Rat4 = Verified data |
High | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Extensively metabolised and around 90% of metabolites eliminated in the urine | A5 A = EU regulatory and evaluation data as published by EC, EFSA (RAR, DAR & Conclusion dossiers), EMA (e.g. EU Annex III PIC DGD) (EU - Pesticides database; EFSA Scientific Publications ) 5 = Verified data used for regulatory purposes |
- | ||||||||
| Health issues |
|
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Possible blood, kidneys, liver and gastrointestinal tract toxicant | ||||||||||||||||||||||||||||
| Handling issues |
|
|
|||
|---|---|---|---|---|
|
IMDG Transport Hazard Class 6.1 | |||
|
- | |||
|
Not listed (Not listed) | |||
|
UN2811 | |||
|
Packaging Group III (minor danger) | |||
|
- |
|
|
|
|
||
|---|---|---|---|
|
ketoprofen | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
| Record last updated: | 06/09/2025 |
| Contact: | aeru@herts.ac.uk |
| Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |
© Copyright University of Hertfordshire, 2006-2026. All Rights Reserved
Your use of this website and its various databases is subject to the terms detailed in the University of Hertfordshire’s copyright and IPR statement that can be found at https://www.herts.ac.uk/about-us/legal. In addition, your use of this website and its various databases is subject to the terms of this additional Copyright Statement and the database Conditions of use document. Unless explicitly stated otherwise, the content of this website and databases are owned and controlled by the University of Hertfordshire. Site content, including its selection and arrangement, is owned by the University of Hertfordshire and is protected by copyright and other laws. Except as otherwise expressly permitted under copyright law or within the database Conditions of Use document, the content of this site may not be copied, reproduced, republished, downloaded, posted, broadcast or transmitted in any way without first obtaining the University of Hertfordshire’s written permission. By using our databases the user is deemed to have agreed to comply with all of the terms and conditions as described above and within all relevant documentation.





